United States · FDA National Drug Code directory
Kanjinti
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 55513-132_0dfd83de-fa6d-43e4-8fb0-4a7c9b134ca7
- Product NDC
- 55513-132
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- trastuzumab-anns
- Labeler
- Amgen, Inc
- Marketing category
- BLA
- Marketing start / end (source format)
- 20190611
- Source listing expiry
- 20271231
Source-listed ingredients
- TRASTUZUMAB — 420 mg/20mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-01) / 20 mL in 1 VIAL, MULTI-DOSE · 55513-132-01
- 1 VIAL, MULTI-DOSE in 1 CARTON (55513-132-21) / 20 mL in 1 VIAL, MULTI-DOSE · 55513-132-21
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →